The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Benoı̂t Rousseau, Michael B. Foote, Steven B. Maron, Bill H. Diplas, Steve Lu, Guillem Argilés, Andrea Cercek, Luis A. Díaz
Abstract
Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA....
Topics & Concepts
BlockadeImmune checkpointCancer researchG2-M DNA damage checkpointBroad spectrumMutationMedicineBiologyCell cycle checkpointGeneticsChemistryCancerCell cycleGeneCombinatorial chemistryReceptorCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsLung Cancer Treatments and Mutations